The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
I think original moditope experiments in mice were in this particular model:
https://www.taconic.com/mouse-model/black-6-b6ntac?utm_term=c57bl%2F6%20mice&utm_campaign=Popular+Models&utm_source=adwords&utm_medium=ppc&hsa_acc=7198328570&hsa_net=adwords&hsa_grp=79100697242&hsa_ver=3&hsa_kw=c57bl%2F6%20mice&hsa_tgt=kwd-811930280143&hsa_mt=p&hsa_ad=379535582377&hsa_src=g&hsa_cam=6465588166&gclid=Cj0KCQjw9IX4BRCcARIsAOD2OB2_H2qGlsnb8Go_BKs7gybCExLedei8Ru7rKMAD8dOZCTodgbsZFGUaAnYXEALw_wcB
I'm guessing here that different researchers are likely to specify their own Transgenic mouse to best fit their own particular line of research.
I think this particular mouse was for Modi1.
I'm not sure whether Lindy has specified other models in the past.
Crumbs,
Thanks, I had found several companies who produce transgenic mice including this one.
The link Inan posted this morning was a paper produced in 2007 suggesting that CD4 could destroy tumours. They used three different sorts of mice. My question was whether these related to the mice used by Scancell in the MODI1 preclinical research. Inan has suggested it was only one type used by Scancell. Is this like one of the three used in the 2007 research?
Thanks crumbs.
I see you can specify sex and age etc but not colour LOL
They come from a company called Taconic
https://www.jax.org/
I expect the mice are from the Jackson Lab?
The idea as I understand it is to make the tumours as close to human tumours as possible.
https://en.wikipedia.org/wiki/Genetically_modified_mouse
"Transgenic mice generated to carry cloned oncogenes and knockout mice lacking tumor suppressing genes have provided good models for human cancer. Hundreds of these oncomice have been developed covering a wide range of cancers affecting most organs of the body and they are being refined to become more representative of human cancer.[9] The disease symptoms and potential drugs or treatments can be tested against these mouse models."
https://www.taconic.com/transgenic-mouse-model/abb-knockouttransgenic-hla-dr4#:~:text=Abb%20Knockout%2FTransgenic%20HLA%2DDR4&text=The%20HLA%2DDR4%20allele%20is,rheumatoid%20arthritis%20and%20multiple%20sclerosis.&text=The%20transgenic%20offspring%20were%20bred,Abb%20knockout%20on%20B6%20background).
Ray,
Yes, I thought producing mice was a specialised undertaking which is why I questioned the claim that Scancell have produced their own. Was it just one type that they specified? Was it of a type they knew would be successful with MODI1?
Lindy specified her own transgenic mouse and they commissioned a company to produce them.
Inan has previously posted a link for the specific mouse on a company's website.
Quite weird as I remember it, similar to a supermarket website complete with basket and checkout.
How they manage to keep the mice in the basket has always puzzled me.
Inan,
I understand the control arm thing but why give them a placebo?
Do you have any links to how Scancell developed their own mice?
this is well worth a read ............... and pretty well explains why getting the "Platform" correct plays IMHO a more important role than any other against Cancer and Virus ....
Critical to almost all functions of the adaptive immune response is the activation and programming of T cells from their naïve/resting state. Although there is much more to be learned, we now have a good basic understanding of the signals and cell types involved in the various stages of the T cell response initiated within the secondary lymphoid organs (SLOs). To provide a comprehensive overview, this review will summarize the T cell response broken down into three major stages: activation, differentiation, and memory formation. We will then assemble these components into a description of the anatomy of an immune response and its relationship to productive immune protection.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4089090/
Scancell developed there own Mouse ...
and even mice have control arms
Inan,
Interesting article, thanks.
There were different results in the different mouse models used (MataHari, Marilyn and Rebecca). Do you know how these relate to the model(s) used by Scancell in the MODI1?
While on the mouse topic, a question I asked a while ago that no one answered was
Why are some of the mice given a placebo?
Scancell have not directly looked at this area in the Pre-clinical but Scancell is aware of what a CD4 can do hence inclusion in the SCIB1 and SCIB2 vaccine ...
we can picture a communication triangle in which tumor-specific CD4 cells activate NK cells via a DC bridge and/or NK cells help to sustain the CD4 response through the activation of DCs. A variation of this scenario comes from a previous report suggesting that CD4 T cells might also partner with tumor-infiltrating macrophages.17,22 At first glance, such a duo might seem less likely than that of the CD4/NK cell partnership, given that tumor-infiltrating macrophages have been shown to support tumor growth by promoting angiogenesis and tissue remodeling and repair.59,60 However, CD4 cells are effective educators of other cells: they can license DCs to activate CD8 killers,43 they can educate DCs to perpetuate oral tolerance,61 and they can induce B cells to switch to a different class of antibody. It is only a small step to suppose that tumor-specific CD4 cells could recognize tumor-infiltrating macrophages, via cross-presented tumor antigens, and alter their phenotype from “tumor-nurturing” to “tumor-rejecting.” Overall, it seems that CD4 T cells may partner with many different types of host cells to clear the tumor, something that CD8 cells may be less able to do.
This is why I call them the General ..
coming to a Patient near you .... Modi1